Results of ruthenium irradiation of uveal melanoma.
The follow-up results are presented for the radiotherapeutic treatment of 49 patients with uveal eye melanoma using ruthenium-106 (106Ru/106Rh) applicators. Graded doses were applied and the degree of regression was found to be correlated with the dose at the top of the tumour. Complete regression is found in 66% of the patients treated with a top dose above 150 Gy, in which case the initial tumour prominence diminishes in about three years to a stable disease or to a flat scar. At this dose a marginal increase in complications was observed as compared with lower dose groups. Useful vision could be preserved in 75% of the eyes.
Tjho-Heslinga
R E
RE
Department of Clinical Oncology, Academic Hospital, Leiden, Netherlands.
Kakebeeke-Kemme
H M
HM
Davelaar
J
J
de Vroome
H
H
Bleeker
J C
JC
Oosterhuis
J A
JA
Leer
J W
JW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D012429:Ruthenium Radioisotopes / Q000627:therapeutic use*; D014604:Uveal Neoplasms / Q000532:radiotherapy*
D012429:Ruthenium Radioisotopes